Preventing latent tuberculosis among HIV-infected patients: Efficacious and effective, yet inefficient?

Clinical Infectious Diseases

Volumn 44, Issue 1, 2007, Pages 103-104

  Rieder, Hans L ^a,b  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID;

AFRICA; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; EUROPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; COHORT STUDIES; HIV INFECTIONS; INCIDENCE; ISONIAZID; SWITZERLAND; TUBERCULOSIS; VIRUS LATENCY;

EID: 33845688009     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510093     Document Type: Note

References (12)

1. Krebs A, Farer LS, Snider DE Jr, Thompson NJ. Five years of follow-up of the IUAT trial of isoniazid prophylaxis in fibrotic lesions. Bull Int Union Tuberc Lung Dis 1979; 54:65-9.
2. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60:555-64.
3. Snider DE, Caras GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255:1579-83.
4. American Thoracic Society, Centers for Disease Control and Prevention (CDC). Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:733-5.
5. Blumberg HM. Treatment of latent tuberculosis infection: back to the beginning. Clin Infect Dis 2004; 39:1772-5.
6. Hawken MP, Meme HK, Chakaya JM, et al. Isoniazid preventive therapy for tuberculosis in HIV-1 infected adults: results of a randomized controlled trial. AIDS 1997; 11:875-82.
7. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15:2137-47.
8. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44:94-102 (in this issue).
9. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 2006; 6:413-22.
10. Pai M, Lewinsohn DM. Interferon-α assays for tuberculosis: is anergy the Achilles' heel? Am J Respir Crit Care Med 2005; 172:519-21.
11. Lee LM, Lobato MN, Buskin SE, Morse A, Costa S. Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States. Int J Tuberc Lung Dis 2006; 10:209-14.
12. Snider DE Jr, Farer LS. Preventive therapy for tuberculous infection: an intervention in need of improvement. Am Rev Respir Dis 1984; 130:355-6.